India's pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which increased sales by 19% and 17% respectively, liver therapies, Liv-52 by 17%, and Udiliv 28%.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.